Aurinia Reports Second Quarter 2019 Financial Results and Operational Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Aurinia Pharmaceuticals (AUPH) Misses Q2 EPS by 2c
August 6, 2019 4:46 PM EDTAurinia Pharmaceuticals (NASDAQ: AUPH) reported Q2 EPS of ($0.17), $0.02 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $39 thousand versus the consensus estimate of $50 thousand.
During the past quarter, the Aurinia team has taken multiple steps forward preparing the organization for the next phase of its evolution into a... More
